

References

1. Institute of Medicine. Clinical practice guidelines: directions for a new program. Washington (DC): National Academy Press; 1990.
2. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. *Can J Psychiatry* 2002;47:833–43.
3. Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, and others. The economic burden of schizophrenia in Canada. *Can J Psychiatry* 1999;44:464–72.
4. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. *Can J Psychiatry* 1991;36:239–45.
5. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation [AGREE] Instrument. Available: www.agreecollaboration.org/instrument/. Accessed 2005 Aug 31.
6. Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia. *Can J Psychiatry* 1998;43 Suppl.
7. ISI Research. Reference Manager. Version 10.0. London (UK): ISI Research; 2001.
8. Portney L, Watkins M. Foundations of clinical research: applications to practice. 2nd ed. Upper Saddle River (NJ): Prentice Hall Health; 2000.
9. Coryell W, Keller M, Lavori P, Endicott J. Affective syndromes, psychotic features, and prognosis. I. Depression. *Arch Gen Psychiatry* 1990;47:651–7.
10. Coryell W, Keller M, Lavori P, Endicott J. Affective syndromes, psychotic features, and prognosis. II. Mania. *Arch Gen Psychiatry* 1990;47:658–62.
11. Coryell W, Lavori P, Endicott J, Keller M, VanEerdewegh M. Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six- to 24-month follow-up. *Arch Gen Psychiatry* 1984;41:787–91.
12. Addington J, Leriger E, Addington D. Symptom outcome 1 year after admission to an early psychosis program. *Can J Psychiatry* 2003;48:204–7.
13. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. *Schizophr Bull* 1999;25:173–82.
14. Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, and others. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. *Acta Psychiatr Scand* 2000;102:303–9.
15. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. *Arch Gen Psychiatry* 1991;48:239–46.
16. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry* 1996;153:321–30.
17. Norman RM, Malla AK, Cortese L, Cheng S, Diaz K, McIntosh E, and others. Symptoms and cognition as predictors of community functioning: a prospective analysis. *Am J Psychiatry* 1999;156:400–5.
18. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. *Schizophr Bull* 1988;14:515–42.
19. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2004;161(3):473–9.
20. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. *Am J Psychiatry* 1992;149:1183–8.
21. Malla AK, Norman RM, Manchanda R, Ahmed MR, Scholten D, Harricharan R, and others. One year outcome in first episode psychosis: influence of DUP and other predictors. *Schizophr Res* 2002;54:231–42.
22. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res* 2004;67(2–3):131–42.
23. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, and others. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICES conference to select cognitive domains and test criteria. *Biol Psychiatry* 2004;56(5):301–7.
24. de Vries PJ, Honer WG, Kemp PM, McKenna PJ. Dementia as a complication of schizophrenia. *J Neurol Neurosurg Psychiatry* 2001;70:588–96.
25. Murphy KC. Schizophrenia and velo-cardio-facial syndrome. *Lancet* 2002;359:426–30.
26. Horowitz A, Shifman S, Rivlin N, Pisante A, Darvasi A. A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients. *Schizophr Res* 2005;73(2–3):263–7.
27. Bassett AS, Hodgkinson K, Chow EW, Correia S, Scutt LE, Weksberg R. 22q11 deletion syndrome in adults with schizophrenia. *Am J Med Genet* 1998;81:328–37.
28. Wiehahn GJ, Bosch GP, du Preez RR, Pretorius HW, Karayiorgou M, Roos JL. Assessment of the frequency of the 22q11 deletion in Afrikaner schizophrenic patients. *Am J Med Genet (Neuropsychiatric Genet)* 2005;129B:20–2.
29. Gewirtz G, Squires-Wheeler E, Sharif Z, Honer WG. Results of computerised tomography during first admission for psychosis. *Br J Psychiatry* 1994;164:789–95.
30. Lubman DI, Velakoulis D, McGorry PD, Smith DJ, Brewer W, Stuart G, and others. Incidental radiological findings on brain magnetic resonance imaging in first-episode psychosis and chronic schizophrenia. *Acta Psychiatr Scand* 2002;106:331–6.
31. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. *JAMA* 1999; 82:36–9.
32. Smith GN, MacEwan GW, Ancill RJ, Honer WG, Ehmann TS. Diagnostic confusion in treatment-refractory psychotic patients. *J Clin Psychiatry* 1992;53:197–200.
33. Honer WG, Smith GN, MacEwan GW, Kopala L, Altman S, Yorkston N, and others. Diagnostic reassessment and treatment response in schizophrenia. *J Clin Psychiatry* 1994;55:528–32.
34. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. *Schizophr Bull* 1990;16:571–89.
35. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale. *Schizophr Res* 1994;11:239–44.
36. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, and others. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA* 1990;264:2511–8.
37. Addington J, el Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. *Am J Psychiatry* 1998;155:974–6.
38. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. *Can J Psychiatry* 1991;36:239–45.
39. Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. *Psychiatry Res* 2003;117:127–35.
40. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, and others. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004;161(8):1334–49.
41. Committee CDACPE. Canadian clinical practice guidelines for the prevention and management of diabetes in Canada. *Canadian Journal of Diabetes* 2003;27(Suppl. 2):S1–S152.
42. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW and others. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. *Arch Gen Psychiatry* 2001;58:965–72.
43. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, and others. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2002;159:1018–28.
44. Ritchie CW, Chiu E, Harrigan S, Hall K, Hasset A, Macfarlane S, and others. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. *Int J Geriatr Psychiatry* 2003;18:432–40.
45. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. *Am J Psychiatry* 1999;156:1138–48.
46. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. *Am J Psychiatry* 2004;161(3):414–25.
47. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. *J Clin Psychiatry* 2001;62(Suppl 7):22–31.
48. Kane JM, Eerdeken M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. *Am J Psychiatry* 2003;160:1125–32.
49. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. *Int J Neuropsychopharmacol* 2003;6:97–102.
50. Murray M, Bullard M, Grafstien EftCaNG. Revisions to the Canadian Emergency Department Triage and Acuity Scale Implementation Guidelines. *Can J Emerg Med* 2004;6(6):421–7.
51. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. *J Clin Psychiatry* 2001;62:153–7.

52. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, and others. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. *Am J Emerg Med* 1997;15:335–40.
53. Canadian Pharmacists Association. *Compendium of Pharmaceuticals and Specialties*. Ottawa (ON): Canadian Pharmacists Association; 2004.
54. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, and others. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. *Arch Gen Psychiatry* 2002;59:441–8.
55. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ and others. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. *Am J Psychiatry* 2001;158:1149–51.
56. Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, and others. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. *J Clin Psychiatry* 2004;65(3):386–94.
57. Fenton M, Coutinho ESF, Campbell C. Zuclophenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. *Cochrane Database of Systematic Reviews* 2004; (1).
58. Addington J, van Mastrigt S, Hutchinson J, Addington D. Pathways to care: help seeking behaviour in first episode psychosis. *Acta Psychiatr Scand* 2002;106:358–64.
59. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. *Psychol Med* 2001;31:381–400.
60. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, and others. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry* 2003;160:1396–404.
61. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. *J Clin Psychopharmacol* 1997;17:308–13.
62. Davis JM, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry* 2003;60:553–64.
63. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. *Am J Psychiatry* 2003;160:2063–5.
64. Chengappa KN, Parepally H, Brar JS, Mullen J, Shilling A, Goldstein JM. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. *Can J Psychiatry* 2003;48:187–94.
65. Malla AK, Norman RM, Voruganti LP. Improving outcome in schizophrenia: the case for early intervention. *CMAJ* 1999;160:843–6.
66. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. *Schizophr Bull* 1996;22:305–25.
67. Lieberman JA, Jody D, Geisler S, Alvir J, Loebel AD, Szymanski SR, and others. Time course and biologic correlates of treatment response in first-episode schizophrenia. *Arch Gen Psychiatry* 1993;50:369–76.
68. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. *Acta Psychiatr Scand* 2002;106:286–90.
69. Koreen AR, Siris SG, Chakos MH, Alvir J, Mayerhoff D, Lieberman JA. Depression in first-episode schizophrenia. *Am J Psychiatry* 1993;150:1643–8.
70. Addington D, Addington J, Patten S. Depression in people with first-episode schizophrenia. *Br J Psychiatry Suppl* 1998;172(33):90–2.
71. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. *Schizophr Bull* 1995;21:567–77.
72. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. *Eur Neuropsychopharmacol* 2004;14(2):87–92.
73. Crow TJ, Macmillan JF, Johnson AL, Johnstone EC. The Northwick Park Study of first episodes of schizophrenia. II A randomised controlled trial of prophylactic neuroleptic treatment. *Br J Psychiatry* 1986;148:120–7.
74. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first-admission studies. *Schizophr Bull* 1992;18:185–207.
75. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. *J Clin Psychiatry* 2000;61:833–40.
76. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988;45:789–96.
77. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, and others. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. *Arch Gen Psychiatry* 2001;58:965–72.
78. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry* 2001;158:518–26.
79. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. *Curr Med Chem* 2004;11(3):313–27.
80. Chanpattana W, Chakrabhand ML, Sackeim HA, Kitaroonchai W, Kongsakon R, Techakasem P, and others. Continuation ECT in treatment-resistant schizophrenia: a controlled study. *J ECT* 1999;15:178–92.
81. Tiihonen J, Hallikainen T, Ryyanen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, and others. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. *Biol Psychiatry* 2003;54:1241–8.
82. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. *Cochrane Database of Systematic Reviews* 2004;(1).
83. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. *Am J Psychiatry* 1998;155:751–60.
84. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. *J Clin Psychiatry* 2001;62:757–71.
85. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. *Schizophr Bull* 2002;28:43–61.
86. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. *Schizophr Bull* 1999;25:157–71.
87. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 4th ed. Washington (DC): American Psychiatric Association; 1994.
88. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. *Am J Psychiatry* 1999;156:1138–48.
89. Siris SG. Suicide and schizophrenia. *J Psychopharmacol* 2001;15:127–35.
90. American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. *Am J Psychiatry* 2003;160(Suppl 11):1–60.
91. Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A, and others. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 2003;60:82–91. [erratum appears in *Arch Gen Psychiatry*.2003;60:735].
92. Lindqvist P, Skipworth J. Evidence-based rehabilitation in forensic psychiatry. *Br J Psychiatry* 2000;176:320–3.
93. Hector RI. The use of clozapine in the treatment of aggressive schizophrenia. *Can J Psychiatry* 1998;43:466–72.
94. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. *Am J Psychiatry* 2004;161(8):1324–33.
95. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. *Psychoneuroendocrinology* 2003;28(Suppl 2):1–16.
96. Patton SW, Misri S, Corral MR, Perry KF, Kuan AJ. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. *Can J Psychiatry* 2002;47:959–65.
97. Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. *Am J Psychiatry* 1999;156:1374–9.
98. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. *J Clin Psychiatry* 2001;62:92–100.
99. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. *J Clin Psychiatry* 2001;62:231–8.
100. Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. *J Clin Psychiatry* 2002;63(Suppl 4):24–32.
101. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. *Journal of Nursing Scholarship* 2003;35:237–41.
102. Wirshing DA, Pierre JM, Erhart SM, Boyd JA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. *Psychiatr Clin North Am* 2003;26:165–90.
103. Casey DE. Dyslipidemia and atypical antipsychotic drugs. *J Clin Psychiatry* 2004;65(Suppl 18):27–35.
104. Consensus development conference on antipsychotic drugs and obesity and diabetes. *J Clin Psychiatry* 2004;65(2):267–72.
105. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, and others. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. *Arch Gen Psychiatry* 2002;59:337–45.
106. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, and others. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. *Am J Psychiatry* 2003;160:290–6.
107. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. *J Clin Psychiatry* 2002;63:425–33.
108. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, and others. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. *BMJ* 2002;325:1070.
109. Cutler AJ. Sexual dysfunction and antipsychotic treatment. *Psychoneuroendocrinology* 2003;28(Suppl 1):69–82.
110. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. *Schizophr Res* 1999;35(Suppl):S75–S86.

111. Abraham G, Halbreich U, Friedman RH, Josiassen RC. Bone mineral density and prolactin associations in patients with chronic schizophrenia. *Schizophr Res* 2003;59:17–8.
112. Knegtering H, van der Moolen AE, Castelein S, Kluiters H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? *Psychoneuroendocrinology* 2003;28(Suppl 2):109–23.
113. Atmaca M, Kuloglu M, Tezcan E, Canatan H, Gecici O. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. *Arch Med Res* 2002;33:562–5.
114. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. *Curr Med Chem* 2004;11(3):343–58.
115. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. *Psychoneuroendocrinology* 2003;28(Suppl 2):69–82.
116. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. *J Clin Psychiatry* 1999;60(Suppl 23):25–8.
117. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, and others. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. *Schizophr Res* 2004;66(2–3):101–13.
118. Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. *Curr Med Chem* 2004;11:279–96.
119. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. *J Clin Psychiatry* 2003;64:1075–80.
120. Awad AG, Voruganti LN. Neuroleptic dysphoria: revisiting the concept 50 years later. *Acta Psychiatr Scand Suppl* 2005;427:6–13.
121. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. *J Clin Psychiatry* 2004;65(4):464–70.
122. Miller DD. Review and management of clozapine side effects. *J Clin Psychiatry* 2000;61(Suppl 8):14–7.
123. Zygmont A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. *Am J Psychiatry* 2002;159:1653–64.
124. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *J Clin Psychiatry* 2002;63:892–909.
125. Amador XF, Strauss DH, Yale SA, Gorman JM. Awareness of illness in schizophrenia. *Schizophr Bull* 1991;17:113–32.
126. Mintz AR, Dobson KS, Romney DM. Insight in schizophrenia: a meta-analysis. *Schizophr Res* 2003;61:75–88.
127. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. *Hosp Community Psychiatry* 1990;41:1203–11.
128. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. *J Clin Psychopharmacol* 2003;23:389–99.
129. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. *Schizophr Bull* 1997;23:637–51.
130. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. *Psychiatr Serv* 2003;54:508–16.
131. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. *Br J Psychiatry* 2003;183:197–206.
132. Pekkala E, Merinder L. Psychoeducation for schizophrenia. *Cochrane Database of Systematic Reviews* 2004;(1).
133. Mueser KT, Corrigan PW, Hilton DW, Tanzman B, Schaub A, Gingerich S, and others. Illness management and recovery: a review of the research. *Psychiatr Serv* 2002;53:1272–84.
134. Heinssen RK. Improving medication compliance of a patient with schizophrenia through collaborative behavioral therapy. *Psychiatr Serv* 2002;53:255–7.
135. Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness. *Cochrane Database of Systematic Reviews* 2004;(1).
136. Lehman A. Vocational rehabilitation in schizophrenia. *Schizophr Bull* 1995;21:645–56.
137. McCreadie RG. The Nithsdale schizophrenia surveys. An overview. *Soc Psychiatry Psychiatr Epidemiol* 1992;27:40–5.
138. Bailey EL, Ricketts SK, Becker DR, Xie H, Drake RE. Do long-term day treatment clients benefit from supported employment? *Psychiatr Rehabil J* 1998;22:24–9.
139. Bond GR, Dietzen LL, McGrew JH, Miller LD. Accelerating entry into supported employment for persons with severe psychiatric disabilities. *Rehabil Psychol* 1995;40:75–94.
140. Chandler D, Meisel J, Hu T, McGowen M, Madison K. A capitated model for a cross-section of severely mentally ill clients: employment outcomes. *Community Ment Health J* 1997;33:501–16.
141. Drake RE, Becker DR, Biesanz JC, Wyzik PF, Torrey WC. Day treatment versus supported employment for persons with severe mental illness: a replication study. *Psychiatr Serv* 1996;47:1125–7.
142. Lehman AF, Goldberg R, Dixon LB, McNary S, Postrado L, Hackman A, and others. Improving employment outcomes for persons with severe mental illnesses. *Arch Gen Psychiatry* 2002;59:165–72.
143. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. *J Nerv Ment Dis* 2003;191(8):515–23.
144. Bond GR, Resnick SG, Drake RE, Xie H, McHugo GJ, Bebout RR. Does competitive employment improve nonvocational outcomes for people with severe mental illness? *J Consult Clin Psychol* 2001;69:489–501.
145. Lehman A. Vocational rehabilitation in schizophrenia (Review). *Database of Abstracts of Reviews of Effectiveness* 2002. Volume 2. June 2002.
146. McFarlane WR, Dushay RA, Deakins SM, Stastny P, Lukens EP, Toran J, and others. Employment outcomes in family-aided assertive community treatment. *Am J Orthopsychiatry* 2000;70:203–14.
147. Fuller TR, Oka M, Otsuka K, Yokoyama N, Liberman RP, Niwa SI. A hybrid supported employment program for persons with schizophrenia in Japan. *Psychiatr Serv* 2000;51:864–6.
148. Mueser KT, Becker DR, Torrey WC, Xie H, Bond GR, Drake RE, and others. Work and nonvocational domains of functioning in persons with severe mental illness: a longitudinal analysis. *J Nerv Ment Dis* 1997;185:419–26.
149. Torrey WC, Mueser KT, McHugo GH, Drake RE. Self-esteem as an outcome measure in studies of vocational rehabilitation for adults with severe mental illness. *Psychiatr Serv* 2000;51:229–33.
150. Campbell A, McCreadie RG. Occupational therapy is effective for chronic schizophrenic day-patients. *British Journal of Occupational Therapy* 1983;46:327–9.
151. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. *Schizophr Bull* 2000;26:21–46.
152. Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. *Am J Psychiatry* 1996;153:607–17.
153. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Martindale B, and others. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. *Psychol Med* 2002;32:783–91.
154. Robertson L, Connaughton J, Nicol M. Life skills programmes for chronic mental illnesses. *Cochrane Database of Systematic Reviews* 2004;(1).
155. Bellack AS, Turner SM, Hersen M, Luber RF. An examination of the efficacy of social skills training for chronic schizophrenic patients. *Hosp Community Psychiatry* 1984;35:1023–8.
156. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, and others. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. *Arch Gen Psychiatry* 1986;43:633–42.
157. Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. *Am J Psychiatry* 1998;155:1087–91.
158. Slade M, Priebe S. Are randomised controlled trials the only gold that glitters? *Br J Psychiatry* 2001;179:286–7.
159. Dickerson FB. Cognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies. *Schizophr Res* 2000;43(2–3):71–90.
160. Norman RM, Townsend LA. Cognitive-behavioural therapy for psychosis: a status report. *Can J Psychiatry* 1999;44:245–52.
161. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, and others. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. *Psychol Med* 2002;32:763–82.
162. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. *J Nerv Ment Dis* 2001;189:278–87.
163. Jones C, Cormac I, Campbell C, Silveira da Mota Neto J. Cognitive behaviour therapy for schizophrenia. *Cochrane Database of Systematic Reviews* 2004;(1).
164. Gumley A, O'Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. *Psychol Med* 2003;33:419–31.
165. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkotter J, Hambrecht M, and others. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. *Acta Psychiatr Scand* 2004;110(1):21–8.
166. Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. *Br J Psychiatry* 2002;180:523–7.
167. Kuipers E, Fowler D, Garety P, Chisholm D, Freeman D, Dunn G, and others. London – East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: Follow-up and economic evaluation at 18 months. *Br J Psychiatry* 1998;173:61–8.
168. Cochrane JJ, Goering PN, Rogers JM. The mental health of informal caregivers in Ontario: an epidemiological survey. *Am J Public Health* 1997;87:2002–7.
169. Baronet AM. Factors associated with caregiver burden in mental illness: a critical review of the research literature. *Clin Psychol Rev* 1999;19:819–41.
170. Mueser KT, Webb C, Pfeiffer M, Gladis M, Levinson DF. Family burden of schizophrenia and bipolar disorder: perceptions of relatives and professionals. *Psychiatr Serv* 1996;47:507–11.

171. Runions J, Prudo R. Problem behaviours encountered by families living with a schizophrenic member. *Can J Psychiatry* 1983;28:382–386.
172. Pitschel-Walz G, Leucht S, Bauml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia—a meta-analysis. *Schizophr Bull* 2001;27:73–92.
173. Hazel NA, McDonnell MG, Short RA, Berry CM, Voss WD, Rodgers ML, and others. Impact of multiple-family groups for outpatients with schizophrenia on caregivers' distress and resources. *Psychiatr Serv* 2004;55:35–41.
174. Mullen A, Murray L, Happell B. Multiple family group interventions in first episode psychosis: enhancing knowledge and understanding. *Int J Ment Health Nurs* 2002;11:225–32.
175. McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and schizophrenia: a review of the literature. *Journal of Marital and Family Therapy* 2003;29:223–45.
176. Barrowclough C, Tarrier N, Lewis S, Sellwood W, Mainwaring J, Quinn J, and others. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. *Br J Psychiatry* 1999;174:505–11.
177. Twamley EW, Jeste DV, Bellack AS. A review of cognitive training in schizophrenia. *Schizophr Bull* 2003;29:359–82.
178. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? *Schizophr Bull* 2000;26:119–36.
179. Goldberg TE, Weinberger DR. Schizophrenia, training paradigms, and the Wisconsin Card Sorting Test redux. *Schizophr Res* 1994;11:291–6.
180. Kurtz MM, Moberg PJ, Gur RC, Gur RE. Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. *Neuropsychol Rev* 2001;11:197–210.
181. Bark N, Revheim N, Huq F, Khalderov V, Ganz ZW, Medalia A. The impact of cognitive remediation on psychiatric symptoms of schizophrenia. *Schizophr Res* 2003;63:229–35.
182. Velligan DI, Bow-Thomas CC. Two case studies of cognitive adaptation training for outpatients with schizophrenia. *Psychiatr Serv* 2000;51:25–9.
183. Hayes RL, McGrath JJ. Cognitive rehabilitation for people with schizophrenia and related conditions. *Cochrane Database of Systematic Reviews* 2004;(1).
184. Krabbendam L, Aleman A. Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies. *Psychopharmacology* 2003;169:376–82.
185. Wykes T, van der GM. Is it time to develop a new cognitive therapy for psychosis—cognitive remediation therapy (CRT)? *Clin Psychol Rev* 2001;21:1227–56.
186. Mead S, Copeland ME. What recovery means to us: consumers' perspectives. *Community Ment Health J* 2000;36:315–28.
187. Anthony WA. A recovery-oriented service system: setting some system level standards. *Psychiatr Rehabil J* 2000;24:159–68.
188. Chamberlin J, Rogers ES, Ellison ML. Self-help programs: description of their characteristics and their members. *Psychiatric Rehabilitation Journal* 1996;19(3):33–42.
189. Soloman P, Draine J. The state of knowledge of the effectiveness of consumer provided services. *Psychiatr Rehabil J* 2001;25:20–7.
190. Felton CJ, Stastny P, Shern DL, Blanch A, Donahue SA, Knight E, and others. Consumers as peer specialists on intensive case management teams: impact on client outcomes. *Psychiatr Serv* 1995;46:1037–44.
191. Soloman P. Peer support/peer provided services underlying processes, benefits, and critical ingredients. *Psychiatric Rehabilitation Journal* 2004;27(4):392–401.
192. Corrigan PW, Garman AN. Considerations for research on consumer empowerment and psychosocial interventions. *Psychiatr Serv* 1997;48:347–52.
193. Davidson L, Chhiman M, Kloos B, Weingarten R, Stayner D, Tebes JK. Peer support among individuals with severe mental illness: a review of the evidence. *Clin Psychol Sci Pract* 1999;6:165–87.
194. Resnick SG, Rosenheck RA, Lehman AF. An exploratory analysis of correlates of recovery. *Psychiatr Serv* 2004;55(5):540–7.
195. Leung D, De Sousa L. A vision and mission for peer support-stakeholder perspectives. *International Journal of Psychosocial Rehabilitation* 2002;7:5–12.
196. Link BG, Struening EL, Neese-Todd S, Asmussen S, Phelan JC. Stigma as a barrier to recovery: the consequences of stigma for the self-esteem of people with mental illnesses. *Psychiatr Serv* 2001;52:1621–6.
197. Corrigan P, Thompson V, Lambert D, Sangster Y, Noel JG, Campbell J. Perceptions of discrimination among persons with serious mental illness. *Psychiatr Serv* 2003;54(8):1105–10.
198. Corrigan PW, Lundin R. Don't call me nuts! Coping with the stigma of mental illness. Tinley Park (IL): Recovery Press; 2001.
199. Corrigan PW, River LP, Lundin RK, Penn DL, Uphoff-Wasowski K, Campion J, and others. Three strategies for changing attributions about severe mental illness. *Schizophr Bull* 2001;27:187–95.
200. Addington DD, Azorin JM, Falloon IR, Gerlach J, Hirsch SR, Siris SG. Clinical issues related to depression in schizophrenia: an international survey of psychiatrists. *Acta Psychiatr Scand* 2002;105:189–95.
201. Craig T, Hwang MY, Bromet EJ. Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. *Am J Psychiatry* 2002;159:592–8.
202. Mueser KT, Salyers MP, Rosenberg SD, Ford JD, Fox L, Carty P. Psychometric evaluation of trauma and posttraumatic stress disorder assessments in persons with severe mental illness. *Psychol Assess* 2001;13:110–7.
203. Norman RM, Malla AK, Cortese L, Diaz F. Aspects of dysphoria and symptoms of schizophrenia. *Psychol Med* 1998;28:1433–41.
204. Delespaul P, deVries M, van Os J. Determinants of occurrence and recovery from hallucinations in daily life. *Soc Psychiatry Psychiatr Epidemiol* 2002;37:97–104.
205. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. *Schizophr Res* 2001;51:171–80.
206. Power PJ, Bell RJ, Mills R, Herrman-Doig T, Davern M, Henry L, and others. Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. *Aust N Z J Psychiatry* 2003;37:414–20.
207. Trower P, Birchwood M, Meaden A, Byrne S, Nelson A, Ross K. Cognitive therapy for command hallucinations: randomised controlled trial. *Br J Psychiatry* 2004;184:312–20.
208. Kingsep P, Nathan P, Castle D. Cognitive behavioural group treatment for social anxiety in schizophrenia. *Schizophr Res* 2003;63:121–9.
209. Norman RM, Malla AK, McLean TS, McIntosh EM, Neufeld RW, Voruganti LP, and others. An evaluation of a stress management program for individuals with schizophrenia. *Schizophr Res* 2002;58:293–303.
210. Addington J, Addington D. Effect of substance misuse in early psychosis. *Br J Psychiatry Suppl* 1998;172(33):134–6.
211. Weiser M, Reichenberg A, Grotto I, Yasvitzky R, Rabinowitz J, Lubin G, and others. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. *Am J Psychiatry* 2004;161:1219–23.
212. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *Br J Psychiatry* 2004;184:110–7.
213. Rosenberg SD, Drake RE, Wolford GL, Mueser KT, Oxman TE, Vidaver RM, and others. Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. *Am J Psychiatry* 1998;155:232–8.
214. Ziedonis DM, Trudeau K. Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model. *Schizophr Bull* 1997;23:229–38.
215. Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated treatment for dual disorders: a guide to effective practice. New York: Guilford Press; 2003.
216. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. *Community Ment Health J* 2003;39:189–202.
217. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. *Psychiatr Rehabil J* 2004;27(4):360–74.
218. Carey KB, Maisto SA, Carey MP, Gordon CM, Correia CJ. Use of legal drugs by psychiatric outpatients: benefits, costs, and change. *Cognitive and Behavioral Practice* 1999;6:15–22.
219. McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. *Biol Psychiatry* 1995;37:550–2.
220. Greer LA, Weerasekera P, Linder B, Goldberg JO. Couples communication skills training for schizophrenia. *Can J Psychiatry* 1997;42:666–7.
221. Greer LA, Goldberg JO, Weerasekera P. Prenatal planning for people with schizophrenia: Integrating individual and couple-level interventions. *Psychiatr Rehabil Skills* 1997;2(1):37–48.
222. Feinleib M. A dictionary of epidemiology. 4th ed. Last JM, Spasoff RA, Harris SS, editors. [book review] *Am J Epidemiol* 2001;154(1):93–4.
223. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. *Schizophr Bull* 1991;17:325–51.
224. Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. *Br J Psychiatry Suppl* 1998;172(33):66–70.
225. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, and others. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry* 2003;160(8):1396–404.
226. Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. *J Am Acad Psychoanal Dyn Psychiatry* 2003;31:141–54.
227. Wolff N. Using randomized controlled trials to evaluate socially complex services: problems, challenges and recommendations. *J Ment Health Policy Econ* 2000;3:97–109.
228. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. *Milbank Q* 1996;74:511–44.
229. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. *Psychol Med* 2001;31:381–400.
230. Gater R, de Almeida e Sousa, Barrientos G, Caraveo J, Chandrashekar CR, Dhadphale M, and others. The pathways to psychiatric care: a cross-cultural study. *Psychol Med* 1991;21:761–74.

231. Cougnard A, Kalmi E, Desage A, Misdrahi D, Abalan F, Brun-Rousseau H, and others. Pathways to care of first-admitted subjects with psychosis in South-Western France. *Psychol Med* 2004;34(2):267–76.
232. Norman RM, Malla AK, Verdi MB, Hassall LD, Fazekas C. Understanding delay in treatment for first-episode psychosis. *Psychol Med* 2004;34(2):255–66.
233. Addington D, el Guebaly N, Chandarana P, Atkinson M. Canadian clinical practice guidelines for the treatment of schizophrenia: adherence and awareness. *Can Psychiatr Assoc Bull* 2000; 32(6):164–7.
234. Reda S, Makhoul S. Prompts to encourage appointment attendance for people with serious mental illness. *Cochrane Database of Systematic Reviews* 2004;(2).
235. Edwards J, Harrigan SM, McGorry PD, Amminger PG. Duration of untreated psychosis (DUP) and outcome in schizophrenia. *Psychol Med* 2002;32:563–4.
236. Malla A, Norman R, McLean T, Scholten D, Townsend L. A Canadian programme for early intervention in non-affective psychotic disorders. *Aust N Z J Psychiatry* 2003;37:407–13.
237. Pelosi AJ, Birchwood M. Is early intervention for psychosis a waste of valuable resources? *Br J Psychiatry* 2003;182:196–8.
238. Birchwood M, Smith J, MacMillan F, Hogg B, Prasad R, Harvey C, and others. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. *Psychol Med* 1989;19:649–56.
239. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, and others. Recovery from psychotic illness: a 15- and 25-year international follow-up study. *Br J Psychiatry* 2001;178:506–17.
240. Norman RM, Townsend L, Malla AK. Duration of untreated psychosis and cognitive functioning in first-episode patients. *Br J Psychiatry* 2001;179:340–5.
241. Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrójo M, and others. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. *BMJ* 2004;329(7474):1067.
242. Scholten DJ, Malla AK, Norman RM, McLean TS, McIntosh EM, McDonald CL, and others. Removing barriers to treatment of first-episode psychotic disorders. *Can J Psychiatry* 2003;48:561–5.
243. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, and others. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. *Arch Gen Psychiatry* 2004;61:143–50.
244. Malla AM, Norman RM. Treating psychosis: is there more to early intervention than intervening early? *Can J Psychiatry* 2001;46:645–48.
245. Kuipers E, Holloway F, Rabe-Hesketh S, Tennakoon L. An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST). *Soc Psychiatry Psychiatr Epidemiol* 2004;39(5):358–63.
246. Thornicroft G, Tansella M. Components of a modern mental health service: a pragmatic balance of community and hospital care: overview of systematic evidence. *Br J Psychiatry* 2004;185:283–90.
247. Quirk A, Lelliott P. What do we know about life on acute psychiatric wards in the UK? A review of the research evidence. *Soc Sci Med* 2001;53:1565–74.
248. Tomov T. Mental health reforms in Eastern Europe. *Acta Psychiatr Scand Suppl* 2001;410:21–6.
249. Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiters H, and others. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care. *Health Technol Assess* 2001;5:1–75.
250. Marshall M, Crowther R, Almaraz-Serrano AM, Tyrer P. Day hospital versus out-patient care for psychiatric disorders. *Cochrane Database of Systematic Reviews* 2004;(1).
251. Audini B, Marks IM, Lawrence RE, Connolly J, Watts V. Home-based versus out-patient/in-patient care for people with serious mental illness. Phase II of a controlled study. *Br J Psychiatry* 1994;165:204–10.
252. Knapp M, Beecham J, Koutsogeorgopoulou V, Hallam A, Fenyó A, Marks IM, and others. Service use and costs of home-based versus hospital-based care for people with serious mental illness. *Br J Psychiatry* 1994;165:195–203.
253. Marks IM, Connolly J, Muijen M, Audini B, McNamee G, Lawrence RE. Home-based versus hospital-based care for people with serious mental illness. *Br J Psychiatry* 1994;165:179–94.
254. Durbin J, Goering P, Cochrane J, Macfarlane D, Sheldon T. Needs-based planning for persons with schizophrenia residing in board-and-care homes. *Schizophr Bull* 2004;30(1):123–32.
255. Hugo M, Smout M, Bannister J. A comparison in hospitalization rates between a community-based mobile emergency service and a hospital-based emergency service. *Aust N Z J Psychiatry* 2002;36:504–8.
256. Von Korff M, Goldberg D. Improving outcomes in depression. *BMJ* 2001;323:948–9.
257. Tyrer P, Coid J, Simmonds S, Joseph P, Marriott S. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality. *Cochrane Database of Systematic Reviews* 2004;(1).
258. Burns T, Fioritti A, Holloway F, Malm U, Rossler W. Case management and assertive community treatment in Europe. *Psychiatr Serv* 2001;52:631–6.
259. Simmonds S, Coid J, Joseph P, Marriott S, Tyrer P. Community mental health team management in severe mental illness: a systematic review. *Br J Psychiatry* 2001;178:497–502.
260. Kanter J. Clinical case management: definition, principles, components. *Hosp Community Psychiatry* 1989;40:361–8.
261. Rapp CA. Theory, principles and methods of the strengths model of case management. In: Harris MBH, editor. *Case management for mentally ill patients: theory and practice*. Langhorne (PA): Harwood Academy Publishers, 1993. p 143–64.
262. Anthony WA, Cohen M, Farkas M, Cohen BF. The chronically mentally ill case management—more than a response to a dysfunctional system. *Community Ment Health J* 1988;24:219–28.
263. Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. *Schizophr Bull* 1998;24:37–74.
264. Scott JE, Dixon LB. Assertive community treatment and case management for schizophrenia. *Schizophr Bull* 1995;21:657–68.
265. Lauriello J, Bustillo J, Keith SJ. A critical review of research on psychosocial treatment of schizophrenia. *Biol Psychiatry* 1999;46:1409–17.
266. Latimer EA. Economic impacts of assertive community treatment: a review of the literature. *Can J Psychiatry* 1999;44:443–54.
267. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 2004;(1).
268. Surles RC, Blanch AK, Shern DL, Donahue SA. Case management as a strategy for systems change. *Health Aff (Millwood)* 1992;11:151–63.
269. Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 2004;(1).
270. Tempier R, Pawliuk N, Perreault M, Steiner W. Satisfaction with clinical case management services of patients with long-term psychoses. *Community Ment Health J* 2002;38:51–9.
271. Lesage AD, Gelinas D, Robitaille D, Dion E, Frezza D, Morissette R. Toward benchmarks for tertiary care for adults with severe and persistent mental disorders. *Can J Psychiatry* 2003;48:485–92.
272. Trainor JN, Morrell-Bellai TL, Ballantyne R, Boydell KM. Housing for people with mental illnesses: a comparison of models and an examination of the growth of alternative housing in Canada. *Can J Psychiatry* 1993;38:494–501.
273. McHugo GJ, Bebout RR, Harris M, Cleghorn S, Herring G, Xie H, and others. A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness. *Schizophr Bull* 2004;30(4):969–82.
274. Friedrich RM, Hollingsworth B, Hradek E, Friedrich HB, Culp KR. Family and client perspectives on alternative residential settings for persons with severe mental illness. *Psychiatr Serv* 1999;50:509–14.
275. Shepherd G, Murray A. Residential care. *Textbook of community psychiatry*. Oxford (UK): Oxford University Press; 2001. p 309–20.
276. Thornicroft G, Bebbington P. Deinstitutionalisation—from hospital closure to service development. *Br J Psychiatry* 1989; 155:739–53.
277. Leff J. Aiding resocialization of the chronic psychotic patient. *Int Clin Psychopharmacol* 1997;12(Suppl 4):S19–S24.
278. Malla AK, Norman RM. Prodromal symptoms in schizophrenia. *Br J Psychiatry* 1994;164:487–93.
279. Herz MI, Lambert JS. Prodromal symptoms and relapse prevention in schizophrenia. *Schizophr Bull* 1995;21:541–51.
280. Norman RM, Malla AK. Prodromal symptoms of relapse in schizophrenia: a review. *Schizophr Bull* 1995;21:527–39.
281. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. *Am J Med Genet* 2002;114:929–37.
282. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, and others. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. *Schizophr Res* 2003;60(1):21–32.
283. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, and others. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry* 2002;59:921–8.
284. McGlashan TH. Commentary: progress, issues, and implications of prodromal research: an inside view. *Schizophr Bull* 2003;29(4):851–8.
285. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, and others. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. *Schizophr Res* 2003;61:7–18.
286. Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, and others. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the “prodromal” sample. *Schizophr Res* 2003;61:19–30.
287. Morrison AP, Renton JC, Williams S, Dunn H, Knight A, Kreutz M, and others. Delivering cognitive therapy to people with psychosis in a community mental health setting: an effectiveness study. *Acta Psychiatr Scand* 2004; 110(1):36–44.
288. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, and others. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1–12.

